

Nina Tunariu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/792631/publications.pdf>

Version: 2024-02-01

88
papers

11,324
citations

81743

39
h-index

58464

82
g-index

89
all docs

89
docs citations

89
times ranked

15827
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
2	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	13.9	1,796
3	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. <i>Science</i> , 2018, 359, 920-926.	6.0	1,199
4	Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 162-174.	5.1	450
5	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	5.8	366
6	Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition. <i>Cancer Discovery</i> , 2017, 7, 1006-1017.	7.7	341
7	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014, 6, 254ra125.	5.8	298
8	Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer. <i>European Urology</i> , 2019, 76, 469-478.	0.9	269
9	MEtastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 81-92.	0.9	230
10	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology</i> , 2015, 67, 795-802.	0.9	195
11	Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. <i>Journal of Clinical Oncology</i> , 2011, 29, 1271-1279.	0.8	189
12	Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. <i>Cancer Discovery</i> , 2018, 8, 1270-1285.	7.7	187
13	Genomics of lethal prostate cancer at diagnosis and castration resistance. <i>Journal of Clinical Investigation</i> , 2020, 130, 1743-1751.	3.9	180
14	Visceral Disease in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 270-273.	0.9	172
15	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	3.2	171
16	Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3195-3204.	0.8	152
17	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	7.7	124
18	SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity. <i>Clinical Cancer Research</i> , 2018, 24, 5585-5593.	3.2	113

#	ARTICLE	IF	CITATIONS
19	Assessment of Treatment Response by Total Tumor Volume and Global Apparent Diffusion Coefficient Using Diffusion-Weighted MRI in Patients with Metastatic Bone Disease: A Feasibility Study. PLoS ONE, 2014, 9, e91779.	1.1	104
20	Therapy monitoring of skeletal metastases with whole-body diffusion MRI. Journal of Magnetic Resonance Imaging, 2014, 39, 1049-1078.	1.9	99
21	Whole-Body MRI: Current Applications in Oncology. American Journal of Roentgenology, 2017, 209, W336-W349.	1.0	89
22	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non- <i>BRCA1/2</i> -Mutant Cancers. Cancer Discovery, 2020, 10, 1528-1543.	7.7	82
23	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology, 2017, 283, 168-177.	3.6	81
24	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. British Journal of Radiology, 2018, 91, 20170577.	1.0	70
25	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. European Urology, 2019, 75, 184-192.	0.9	69
26	Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers. Clinical Cancer Research, 2014, 20, 5672-5685.	3.2	66
27	Rationale for Modernising Imaging in Advanced Prostate Cancer. European Urology Focus, 2017, 3, 223-239.	1.6	62
28	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. Journal of the National Cancer Institute, 2014, 106, dju033.	3.0	59
29	Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. Gut, 2018, 67, 1484-1492.	6.1	59
30	Advanced Solid Tumors Treated with Cediranib: Comparison of Dynamic Contrast-enhanced MR Imaging and CT as Markers of Vascular Activity. Radiology, 2012, 265, 426-436.	3.6	51
31	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. Radiology, 2016, 280, 151-160.	3.6	51
32	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 529-537.	3.7	51
33	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respiratory Medicine, 2019, 7, 523-532.	5.2	50
34	A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Research, 2014, 34, 3663-8.	0.5	50
35	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology, 2019, 292, 273-286.	3.6	46
36	Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology, 2017, 284, 88-99.	3.6	45

#	ARTICLE	IF	CITATIONS
37	miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3830-3838.	3.2	42
38	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. <i>PLoS ONE</i> , 2016, 11, e0153840.	1.1	40
39	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. <i>Investigative Radiology</i> , 2018, 53, 96-102.	3.5	36
40	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 280-284.	1.0	33
41	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 485-493.	0.9	30
42	The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. <i>BMC Cancer</i> , 2017, 17, 456.	1.1	30
43	Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. <i>European Radiology</i> , 2018, 28, 1687-1691.	2.3	29
44	Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2504-2504.	0.8	27
45	What's New for Clinical Whole-body MRI (WB-MRI) in the 21st Century. <i>British Journal of Radiology</i> , 2020, 93, 20200562.	1.0	26
46	Response evaluation in mesothelioma: Beyond RECIST. <i>Lung Cancer</i> , 2015, 90, 433-441.	0.9	25
47	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.4	25
48	The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸ F-Fluoromethylcholine or ⁶⁸ Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1253-1258.	2.8	24
49	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2022, 81, 1087-1100.	0.4	23
50	Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2506-2506.	0.8	22
51	Quantitative Whole-Body Diffusion-Weighted MR Imaging. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 479-494.	0.6	19
52	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e801-e807.	0.9	16
53	Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials. <i>Clinical Cancer Research</i> , 2020, 26, 4805-4813.	3.2	12
54	An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2503-2503.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 123, 1360-1369.	2.9	10
56	Noise-Corrected, Exponentially Weighted, Diffusion-Weighted MRI (niceDWI) Improves Image Signal Uniformity in Whole-Body Imaging of Metastatic Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 704.	1.3	10
57	Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8556-8556.	0.8	10
58	T2 -adjusted computed diffusion-weighted imaging: A novel method to enhance tumour visualisation. <i>Computers in Biology and Medicine</i> , 2016, 79, 92-98.	3.9	9
59	Microstructure Characterization of Bone Metastases from Prostate Cancer with Diffusion MRI: Preliminary Findings. <i>Frontiers in Oncology</i> , 2018, 8, 26.	1.3	9
60	Metastasis Reporting and Data System for Prostate Cancer in Practice. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2018, 26, 527-542.	0.6	8
61	Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. <i>British Journal of Radiology</i> , 2021, 94, 20200682.	1.0	8
62	Accelerating Whole-Body Diffusion-weighted MRI with Deep Learning-based Denoising Image Filters. <i>Radiology: Artificial Intelligence</i> , 2021, 3, e200279.	3.0	8
63	Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. <i>European Radiology</i> , 2022, , 1.	2.3	8
64	A review on the added value of whole-body MRI in metastatic lobular breast cancer. <i>European Radiology</i> , 2022, 32, 6514-6525.	2.3	8
65	Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 659-667.	2.6	8
66	Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e299-e305.	0.9	6
67	Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC. <i>Cancer Research</i> , 2021, 81, CT019-CT019.	0.4	5
68	High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. <i>Oncotarget</i> , 2017, 8, 104430-104443.	0.8	5
69	Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?. <i>Cancer Imaging</i> , 2022, 22, .	1.2	5
70	Diffusion-Weighted MR Imaging in Oncology. <i>Current Radiology Reports</i> , 2014, 2, 1.	0.4	4
71	Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 548-548.	0.8	4
72	DCE-MRI is more sensitive than IM-M-DWI for assessing anti-angiogenic treatment-induced changes in colorectal liver metastases. <i>Cancer Imaging</i> , 2021, 21, 67.	1.2	4

#	ARTICLE	IF	CITATIONS
73	Elucidating Durable Responses to Immune Checkpoint Inhibition. <i>European Urology</i> , 2020, 78, 639-641.	0.9	3
74	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer – Prevalence and Current Clinical Practice. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
75	Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation – a Single Unit Experience. <i>Cancer Treatment and Research Communications</i> , 2021, 27, 100309.	0.7	2
76	Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase III Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	2
77	Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2043-2043.	0.8	2
78	Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5024-5024.	0.8	2
79	Competing Technology for PET/Computed Tomography. <i>PET Clinics</i> , 2013, 8, 259-277.	1.5	1
80	Whole body – diffusion weighted imaging for the assessment of treatment response in hairy cell leukaemia: A positive first step. <i>EJHaem</i> , 2021, 2, 311-312.	0.4	1
81	A phase I study of 2-hydroxyoleic acid (2-OHOA), a novel sphingomyelin synthase activator in patients (pt) with advanced solid tumors (AST) including refractory high grade gliomas/glioblastomas (GBM): Updated results of the expansion.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14086-e14086.	0.8	1
82	The emerging role of whole-body magnetic resonance imaging in advanced prostate cancer. <i>Minerva Urology and Nephrology</i> , 2021, 73, 141-143.	1.3	0
83	Preliminary evidence of antitumour activity of Ipatasertib (Ipat) and Atezolizumab (ATZ) in glioblastoma patients (pts) with PTEN loss from the Phase 1 Ice-CAP trial (NCT03673787). <i>Neuro-Oncology</i> , 2021, 23, iv10-iv10.	0.6	0
84	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5043-5043.	0.8	0
85	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5071-5071.	0.8	0
86	Update on Clinical Safety and Efficacy of the Novel Oral Dual RAF/MEK Inhibitor RO5126766 (CH5127566) in RAS-mutant Multiple Myeloma. <i>Blood</i> , 2018, 132, 3237-3237.	0.6	0
87	Early response to chemotherapy in malignant pleural mesothelioma assessed using diffusion-weighted MRI: Initial observations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100253.	0.6	0
88	Abstract 2807: HER3 is an actionable target in advanced prostate cancer. <i>Cancer Research</i> , 2022, 82, 2807-2807.	0.4	0